Oncol Lett. 2016 Oct;12(4):2381-2388. doi: 10.3892/ol.2016.4915. Epub 2016 Jul 28.

Expression and potential correlation among Forkhead box protein M1, Caveolin-1 and E-cadherin in colorectal cancer.

Oncology letters

Jing Zhang, Kundong Zhang, Lisheng Zhou, Weidong Wu, Tao Jiang, Jun Cao, Kejian Huang, Zhengjun Qiu, Chen Huang

PMID: 27698803 PMCID: PMC5038523 DOI: 10.3892/ol.2016.4915

Abstract

The aim of the present study was to investigate the expression and functions of Forkhead box protein M1 (FoxM1), Caveolin-1 (Cav-1) and E-cadherin in colorectal cancer (CRC), and to determine the correlations among these proteins in CRC development and progression. The protein expression of FoxM1, Cav-1 and E-cadherin was identified using a human CRC and normal tissue microarray. A standard immunohistochemistry assay was performed employing anti-FoxM1, anti-Cav-1 and anti-E-cadherin antibodies. The clinicopathological significance of FoxM1, Cav-1 and E-cadherin in CRC was determined, and correlations were investigated between FoxM1 and Cav-1, FoxM1 and E-cadherin, Cav-1 and E-cadherin, respectively. The level of FoxM1, Cav-1 and E-Cadherin protein expression in CRC was found to be associated with pathological grade, tumor clinical stages and the presence of metastasis, respectively. Elevated expression of FoxM1 and Cav-1 was observed in the CRC tissues, and a significant correlation was found between the two proteins in CRC. However, it was also observed that FoxM1 was overexpressed while E-cadherin expression was low, indicating that there was a negative correlation between FoxM1 expression and E-cadherin expression. Moreover, there was also a negative correlation between Cav-1 and E-cadherin expression. Overall, the elevated expression of FoxM1 and Cav-1 in a human CRC microarray provided novel clinical evidence to elucidate the fact that they may play a critical role in the development and progression of CRC by negatively regulating E-cadherin expression. Furthermore, the positive correlation between FoxM1 and Cav-1 suggested that the proteins may constitute a novel signaling pathway in human CRC.

Keywords: E-cadherin; caveolin-1; colorectal cancer; foxM1

References

1. Chin J Cancer Res. 2014 Feb;26(1):48-58 - PubMed
2. Cardiovasc Res. 2006 Apr 1;70(1):42-9 - PubMed
3. Eur J Cancer. 2014 Jan;50(1):204-15 - PubMed
4. Cell Cycle. 2013 Aug 15;12(16):2684-90 - PubMed
5. Biochem Pharmacol. 2013 Mar 1;85(5):644-52 - PubMed
6. Oncol Rep. 2014 Jun;31(6):2660-8 - PubMed
7. PLoS One. 2013 Jul 29;8(7):e70858 - PubMed
8. Cancer Genet. 2014 Mar;207 (3):75-82 - PubMed
9. Urol Oncol. 2014 Aug;32(6):855-63 - PubMed
10. Nat Rev Cancer. 2013 Jul;13(7):482-95 - PubMed
11. Cancer Res. 2012 Feb 1;72 (3):655-65 - PubMed
12. J Cell Mol Med. 2008 Aug;12(4):1130-50 - PubMed
13. Neoplasia. 2004 Nov-Dec;6(6):744-50 - PubMed
14. Biochim Biophys Acta. 2014 Apr;1845(2):104-16 - PubMed
15. Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34 - PubMed
16. Cancer Cell Int. 2014 Sep 09;14(1):72 - PubMed
17. Cancer Lett. 2013 Oct 28;340(1):104-12 - PubMed
18. Genome Biol. 2004;5(3):214 - PubMed
19. Cancer Res. 2000 Oct 15;60(20):5870-8 - PubMed
20. Lancet. 2014 Apr 26;383(9927):1490-502 - PubMed
21. Exp Cell Res. 2007 Apr 15;313(7):1307-17 - PubMed
22. Clin Transl Oncol. 2015 Mar;17(3):209-14 - PubMed
23. Anticancer Res. 2014 May;34(5):2427-32 - PubMed
24. Cancer Res. 2012 Aug 15;72(16):4097-109 - PubMed
25. Clin Cancer Res. 2013 Jan 1;19(1):62-72 - PubMed
26. Am J Clin Pathol. 2001 May;115(5):719-24 - PubMed
27. Cell Cycle. 2011 Mar 1;10(5):760-6 - PubMed
28. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
29. Oncol Rep. 2004 May;11(5):957-63 - PubMed
30. Mol Carcinog. 2013 Nov;52(11):859-70 - PubMed
31. Front Oncol. 2013 Mar 05;3:30 - PubMed
32. Gastroenterology. 2007 Apr;132(4):1420-31 - PubMed
33. Clin Cancer Res. 2014 Mar 15;20(6):1477-88 - PubMed
34. PLoS One. 2013;8(1):e54556 - PubMed
35. PLoS One. 2014 Jan 13;9(1):e84551 - PubMed

Publication Types

• Journal Article